IXICO secures new contract for £3.4 million

IXICO broadens its rare disease franchise into SCA3, a rare neurodegenerative condition

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces it has been awarded a £3.4 million contract to run over c.4.5 years by an existing client for a Spinocerebellar Ataxia type 3 (SCA3) trial. SCA3, also known as Machado-Joseph disease, is a rare, neurodegenerative condition resulting in movement disorders, rigidity, muscular atrophy and paralysis. Currently there is no treatment to slow down or reverse the progressive course of this terminal disease. 

For the study, IXICO will provide operational services and advanced AI neuroimaging solutions for volumetric, diffusion and functional magnetic resonance imaging (vMRI, dMRI, rs-fMRI) as well as magnetic resonance spectroscopy (H-MRS) and quantitative susceptibility mapping (QSM). Having singularly focused on neurological disorders since its inception, IXICO has a long and established track record of enabling biopharmaceutical sponsors to realise the full power of neuroimaging in CNS and rare disease clinical trials.

Lammert Albers, Chief Commercial Officer of IXICO, commented:

"SCA3 is an area with clear, unmet medical needs and we are delighted to be chosen as the neuroimaging partner in this spinocerebellar ataxia trial.  Neuroimaging, with its unique ability to reveal extraordinary information about the structural and functional characteristics of the human brain is a powerful tool in CNS studies, and we are proud to support our clients in potentially unlocking new insights into disease progression."

 

For further information please contact:

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

Walbrook PR Ltd

      +44 (0)20 7933 8780

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings


Date: 24/12/2020